WO2019177375A8 - Dérivés de pyrimidine substitués en positions 2, 4 et 5, leur procédé de préparation et composition pharmaceutique pour la prévention ou le traitement du cancer les contenant en tant que principe actif - Google Patents

Dérivés de pyrimidine substitués en positions 2, 4 et 5, leur procédé de préparation et composition pharmaceutique pour la prévention ou le traitement du cancer les contenant en tant que principe actif Download PDF

Info

Publication number
WO2019177375A8
WO2019177375A8 PCT/KR2019/002915 KR2019002915W WO2019177375A8 WO 2019177375 A8 WO2019177375 A8 WO 2019177375A8 KR 2019002915 W KR2019002915 W KR 2019002915W WO 2019177375 A8 WO2019177375 A8 WO 2019177375A8
Authority
WO
WIPO (PCT)
Prior art keywords
same
preventing
pharmaceutical composition
active ingredient
pyrimidine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2019/002915
Other languages
English (en)
Korean (ko)
Other versions
WO2019177375A1 (fr
Inventor
정명호
김주빈
전현호
이윤호
이화
강세인
조서현
강주희
김환
김현경
서경아
손정범
김남두
석지윤
이선화
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Voronoi Inc
Voronoibio Inc
Original Assignee
Voronoi Inc
Voronoibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voronoi Inc, Voronoibio Inc filed Critical Voronoi Inc
Publication of WO2019177375A1 publication Critical patent/WO2019177375A1/fr
Publication of WO2019177375A8 publication Critical patent/WO2019177375A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dérivés de pyrimidine substitués en positions 2, 4 et 5, leur procédé de préparation et une composition pharmaceutique pour la prévention ou le traitement du cancer les contenant en tant que principe actif. Le composé selon l'invention présente une forte capacité inhibitrice vis-à-vis du récepteur du facteur de croissance épidermique (EGFR) de type sauvage ou mutant, et par conséquent, ledit composé peut être utilisé de manière efficace dans le traitement d'un cancer exprimant EGFR de type sauvage ou une mutation d'EGFR. Le composé a une excellente aptitude à inhiber la prolifération des lignées cellulaires du cancer du poumon et peut être particulièrement utile pour le traitement du cancer du poumon.
PCT/KR2019/002915 2018-03-13 2019-03-13 Dérivés de pyrimidine substitués en positions 2, 4 et 5, leur procédé de préparation et composition pharmaceutique pour la prévention ou le traitement du cancer les contenant en tant que principe actif Ceased WO2019177375A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20180029389 2018-03-13
KR10-2018-0029389 2018-03-13
KR20180070258 2018-06-19
KR10-2018-0070258 2018-06-19

Publications (2)

Publication Number Publication Date
WO2019177375A1 WO2019177375A1 (fr) 2019-09-19
WO2019177375A8 true WO2019177375A8 (fr) 2020-06-11

Family

ID=67907894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/002915 Ceased WO2019177375A1 (fr) 2018-03-13 2019-03-13 Dérivés de pyrimidine substitués en positions 2, 4 et 5, leur procédé de préparation et composition pharmaceutique pour la prévention ou le traitement du cancer les contenant en tant que principe actif

Country Status (2)

Country Link
KR (1) KR102782739B1 (fr)
WO (1) WO2019177375A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI798334B (zh) * 2018-01-31 2023-04-11 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｒｂｂ／ｂｔｋ抑制劑
PT3943491T (pt) 2019-03-19 2025-07-28 Voronoi Inc Derivado de heteroarilo, método para a produção do mesmo e composição farmacêutica que compreende o mesmo como componente eficaz
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
KR102383200B1 (ko) * 2019-10-18 2022-04-06 한국화학연구원 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR102467444B1 (ko) * 2019-11-11 2022-11-15 서울대학교산학협력단 이소-엑시구아민 A(iso-exiguamine A) 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 IDO-1 관련 질환의 예방 또는 치료용 약학적 조성물
KR102267662B1 (ko) * 2019-11-19 2021-06-22 한국화학연구원 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
TW202128670A (zh) * 2019-11-26 2021-08-01 大陸商上海翰森生物醫藥科技有限公司 含氮多環類衍生物抑制劑、其製備方法和應用
CN113493420B (zh) * 2020-03-18 2025-04-25 南京迈晟科技有限责任公司 Egfr酪氨酸激酶抑制剂及其用途
AU2021288300A1 (en) * 2020-06-08 2023-02-02 Hongyun Biotech Co., Ltd. Alkenyl pyrimidine compound, preparation method therefor, and application thereof
TW202227425A (zh) * 2020-09-18 2022-07-16 南韓商沃若諾伊生物公司 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CA3224748A1 (fr) * 2021-08-02 2023-02-09 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Nouveaux sels pharmaceutiques et formes polymorphes d'un inhibiteur d'erbb et btk
AU2022322671A1 (en) * 2021-08-05 2024-02-29 Industry-Academic Cooperation Foundation, Yonsei University Pyrimidine derivative, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
NZ713361A (en) * 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
WO2013169401A1 (fr) * 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Composés pour inhiber la prolifération cellulaire dans les cancers induits par l'egfr
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
WO2016054987A1 (fr) * 2014-10-11 2016-04-14 上海翰森生物医药科技有限公司 Inhibiteur d'egfr, et préparation et application associées
CN105601573B (zh) * 2014-11-24 2021-07-02 中国科学院上海药物研究所 2-氨基嘧啶类化合物及其药物组合物和应用

Also Published As

Publication number Publication date
KR102782739B1 (ko) 2025-03-20
WO2019177375A1 (fr) 2019-09-19
KR20190108079A (ko) 2019-09-23

Similar Documents

Publication Publication Date Title
WO2019177375A8 (fr) Dérivés de pyrimidine substitués en positions 2, 4 et 5, leur procédé de préparation et composition pharmaceutique pour la prévention ou le traitement du cancer les contenant en tant que principe actif
CR20210415A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2
PH12020551692A1 (en) 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
EP4520328A3 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
NZ795548A (en) Allosteric egfr inhibitors and methods of use thereof
EP4374858A3 (fr) Dérivés de la benzimidazolone en tant qu'inhibiteurs du récepteur bcl6
EP4360713A3 (fr) Derives de quinazoline utilises comme agents antitumoraux
MX2025011774A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
EP4631507A3 (fr) Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace
WO2019177374A8 (fr) Dérivé de pyrimidine substitué en positions 2, 4 et 5, son procédé de préparation, et composition pharmaceutique le comprenant en tant que principe actif pour la prévention ou le traitement du cancer ou d'une maladie inflammatoire
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
EP4026835A3 (fr) Inhibiteurs de pd-1/pd-l1
EP4371562A3 (fr) Dérivés de la 2-quinolone en tant qu'inhibiteurs du récepteur bcl6
WO2020247701A3 (fr) Inhibiteurs de sarm1
MX2021008667A (es) Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo.
MX2025006620A (es) Compuestos y composiciones como inhibidores de la cinasa c-kit
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
PH12021552898A1 (en) N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
EP4480485A3 (fr) Inhibiteurs de protéine kinase et leurs utilisations pour le traitement de maladies et d'états
WO2020159171A3 (fr) Composition comprenant de la streptonigrine et un agent anticancéreux pour prévenir ou traiter le cancer colorectal
WO2017098051A3 (fr) Préparations combinées de modulateurs de pkm2 et de hmgb1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19766992

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19766992

Country of ref document: EP

Kind code of ref document: A1